COVID-19 Vaccine Corporation receives award to help progress its mRNA vaccine

14 December 2021

AUKLAND: COVID-19 Vaccination Corporation (CVC), New Zealand’s most experienced group of vaccine researchers have been awarded a grant of AUD 50,000 by Pipeline Accelerator, Therapeutic Innovation Australia (TIA).

CVC has previously announced its collaboration with Australia’s BASE Nucleic Acids Biomanufacturing Facility to produce an mRNA COVID-19 vaccine. The award supports this project.

CVC’s vaccine is designed to work differently to currently marketed COVID-19 vaccines, with the main aim of protecting against COVID’s current and future variants. CVC’s design has been recently “stress tested” with the emergence of the Omicron variant. CVC’s vaccine is predicted to maintain 100% coverage of Omicron.

“I am absolutely delighted that CVC has been awarded this TIA grant. We are working very productively with BASE in Queensland and this award cements and supports our continued collaboration,” says Dr Feldman.

“We are very grateful to TIA for being open to awarding grants to New Zealand entitiies such as CVC.  It is typical of the support and collaboration CVC has received when working with Australia’s biotechnology research providers,” he adds.